CGChristine Kim Garcia

Christine Kim Garcia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christine Kim Garcia has a total of 385 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Post-Acute Sequelae of COVID-19 Persist Over 3 Years in Acute Lung Injury/Acute Respiratory Distress Syndrome Survivors But Are Not Associated With Persistent Thromboinflammation or Endothelial Dysfunction

    by Ansley E. Md Jones, Zain Khan, Claire F. McGroder, Scarlett O. Murphy, Christopher Bs Depender, Margarita Mira-Sanchez, Charity O. Mbbs Ogunlusi, Ying Wei, Christine K. Garcia, Matthew R. Baldwin

    IMPORTANCE: Inflammation, endothelial dysfunction, and complement activation are associated with COVID-19 acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). OBJECTIVES: We hypothesized that higher levels of inflammation, endothelial dysfunction, and complement activation implicated in more severe COVID-19 ALI/ARDS are associated with post-acute sequelae of COVID-19 (PASC) phenotypes in the 3 years after hospitalization. DESIGN, SETTING, AND PARTICIPANTS: A single-center prospective cohort of 150 adult survivors of severe and critical COVID-19 from the first wave of the pandemic with sampling weighted to include 50% survivors of mechanical ventilation. MAIN OUTCOMES AND MEASURES: Eleven serum biomarkers at hospital discharge, 4 months, 15 months, and 3 years, and symptoms and physical function at 15 months and 3 years. PASC presence was defined using the 12 symptoms and scoring from the Researching COVID to Enhance Recovery (RECOVER) definition. We tested associations of biomarkers with PASC and symptom phenotypes of post-exertional malaise, fatigue, and brain fog while adjusting for age, sex, body mass index, comorbidities, and days since COVID-19 diagnosis. RESULTS: The mean ( sd ) age of the cohort was 56 years (13); 67% were Hispanic and 25% were Black. PASC was present in 26% of participants at both 15 months and 3 years. PASC and symptom phenotypes at 15 months and 3 years were consistently associated with higher frailty phenotype category, worse short physical performance battery scores, and shorter 6-minute walk distance. Biomarkers of inflammation, including interleukin-6 and soluble tumor necrosis factor receptor-1, endothelial function, including angiopoietin, and complement, including C2, C4b, and C5, were not associated with PASC or symptom phenotypes in cross-sectional or longitudinal analyses. CONCLUSIONS AND RELEVANCE: PASC persists for 3 years after acute COVID-19 ALI/ARDS, is associated with frailty, but not associated with persistently higher levels of inflammatory, endothelial, and complement biomarkers implicated in worse short-term outcomes in acute COVID-19, non-COVID-19 ARDS, and sepsis. Future studies should employ multiomics to elucidate potential mechanisms of PASC.

  • Open Access

    Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation Analysis

    by Justin Oldham, Philip Molyneaux, Manoj Maddali, Chad Newton, John Kim, Sam Konkol, Janelle Pugashetti, Gabrielle Liu, Gillian Goobie, Ayodeji Adegunsoye, et al.

    Progressive interstitial lung disease (ILD) leads to declining lung function and death. New therapies to treat ILD are urgently needed. Here we performed a secondary analysis of proteomic data from ten ILD cohorts across the United States, Canada, and United Kingdom. Causal mediation analysis was used to estimate the effect of plasma proteins previously linked to organ fibrosis in mechanistic studies (exposure) on survival (outcome) through lung function decline (mediator). Of 102 proteins tested in a discovery cohort (n = 1963), 47 were mediated by declining lung function. Of these 47 proteins, 7 showed sustained mediation in an independent validation cohort (n = 1172). Proteins with the strongest mediated effect were amphiregulin and integrin beta six. Sensitivity analysis showed that results were robust to unmeasured confounding. Here we provide epidemiological evidence implicating seven proteins as potentially causal of progressive ILD. These findings build upon mechanistic studies showing a causal link between these proteins and organ fibrosis, supporting their prioritization for therapeutic consideration.

  • ISHLT Consensus Statement on Short Telomere Syndrome and Lung Transplantation: Authors’ Perspective

    by Andrew M. Courtwright, John A. Mackintosh, Jonathan K. Alder, Christine Kim Garcia, Antoine Froidure, Erin Lowery, Don Hayes Jr., Pali Shah, Quentin Philippot, Raphael Borie, et al.


  • Imaging, Pulmonary Function, and Histopathologic Findings of Persistent Fibrosis in a Longitudinal Cohort 3 Years after COVID-19

    by Scarlett O. Murphy, Claire F. McGroder, Mary M. Salvatore, Belinda M. D’sOuza, Kathleen M. Capaccione, Anjali Saqi, Faisal Shaikh, Shannon Benesh, David Zhang, Matthew R. Baldwin, et al.

    Rationale: Survivors of severe coronavirus disease (COVID-19) frequently have persistent radiologic abnormalities beyond one year. Scant data exist for long-term outcomes of COVID-19. Objectives: To characterize a longitudinal multiethnic cohort of COVID-19 survivors 3 years after infection; to identify clinical factors associated with post–COVID-19 fibrotic-like abnormalities; to describe changes in radiologic abnormalities at 4 months, 15 months, and 3 years; and to describe histopathologic features of lung parenchyma from participants with fibrotic-like abnormalities at 3 years. Methods: One hundred two survivors of severe or critical COVID-19 (50% mechanically ventilated, all requiring oxygen supplementation) from a single-center, prospective, longitudinal, multiethnic cohort completed inspiratory and expiratory high-resolution chest imaging, pulmonary function testing, and physical performance testing 3 years after hospitalization. More than 70% participated in earlier follow up visits at 4 and/or 15 months. Factors associated with persistent fibrotic-like abnormalities were examined using multivariable logistic regression with covariate-balanced propensity scores to estimate adjusted associations. For subjects with more than one imaging study, changes in ground-glass opacities, reticulations, and traction bronchiectasis were semiquantitatively analyzed and qualitatively assessed. Five participants with post–COVID-19 fibrosis scores in the top quartile underwent transbronchial biopsy for histopathologic analysis. Results: Fibrotic-like abnormalities, including reticulations and traction bronchiectasis, were present in 61% of survivors of severe or critical COVID-19. In adjusted analyses, fibrotic-like abnormalities were positively associated with male sex, lower body mass index (BMI), shorter leukocyte telomere length, increased severity of illness and mechanical ventilation; they were negatively associated with Black race. Participants with fibrotic-like abnormalities were more likely to have reduced diffusion capacity and reduced 6-minute-walk distance. Reticulations, as assessed by semiquantitative analysis, modestly improved across all time points, even between 15 months and 3 years. Qualitatively, most participants had stable fibrotic-like abnormalities across all time points, with 9% improving from 15 months to 3 years and none worsening. Lung parenchyma from transbronchial biopsies of five individuals with elevated fibrotic scores showed small airway histopathology, consistent with air trapping during expiration, and infrequent interstitial thickening and fibrosis. Conclusions: Despite modest improvements in radiologic fibrotic-like abnormalities 3 years after hospitalization, their continued presence and their association with reduced diffusion capacity and reduced walk distance highlight the long-term consequences of severe COVID-19, which may require further monitoring.


  • Associations of High Attenuation Area–Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities

    by John S. Kim, Catherine L. Debban, Daniel E. Guzman, Riley T. Hannan, Mary Salvatore, Claire McGroder, David Zhang, Anna J. Podolanczuk, Daniel A. Duprez, Shwu-Fan Ma, et al.

    Rationale: High-attenuation area (HAA) is a computed tomography (CT) tool that correlates with lung inflammation and fibrosis. Systemic molecular correlates of HAA (e.g., plasma proteins) may inform biological processes involved in interstitial lung disease. Objectives: To identify plasma proteins that associate with HAA and correlate with a higher probability of developing new-onset fibrotic or subpleural interstitial lung abnormalities (ILAs). Methods: Plasma protein levels were measured using a semiquantitative aptamer-based platform in MESA (the Multi-Ethnic Study of Atherosclerosis; N = 5,486) and SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study; N = 1,781). Linear regression models identified HAA-associated proteins after adjustment for demographic and socioeconomic factors, CT scanner parameters, study center, and batch. Associations of HAA-related proteins with new-onset fibrotic or subpleural ILAs were examined in MESA participants with ILA assessments on full-lung CT 10 years later. Immunohistochemical staining of select proteins was performed in lung tissue from pulmonary fibrosis cases. Measurements and Main Results: There were 75 proteins detected that were significantly associated with HAA in MESA and SPIROMICS. Gene Ontology analysis of these proteins identified processes involved in immune cell chemotaxis and cellular growth and apoptosis. Seven proteins were associated with a higher probability of new-onset fibrotic or subpleural ILAs in MESA, and two of these, junctional adhesion molecule-like protein and GTP cyclohydrolase 1 feedback regulatory protein, stained in areas of fibrosis in lung tissue from patients with interstitial lung disease. Conclusions: Plasma proteins associated with more HAA are involved in immune and cellular processes and associate with new-onset fibrotic-subpleural ILA.


  • Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis

    by Chad A. Newton, Ashwatha Thenappan, Gabrielle Y. Liu, Leda Yazbeck, Cathryn T. Lee, Janelle Vu Pugashetti, Jennifer M. Wang, Ethan White, Kevin R. Flaherty, Elizabeth A. Belloli, et al.

    Rationale: Clinical measures of progressive pulmonary fibrosis (PPF) have been proposed, but their clinical utility remains unclear. Objectives: To determine performance characteristics of lung function–based PPF measures, including new guideline criteria for discriminating clinically relevant outcomes. Methods: A multicenter retrospective cohort analysis was performed to assess the performance characteristics of eight categorical measures of FVC and Dl CO decline, together with PPF guideline criteria (requiring two of the following: worsening respiratory symptoms, absolute decline in FVC ≥5% or Dl CO ≥15%, or radiological progression) for discriminating 2-year death or lung transplant among patients fibrotic interstitial lung disease from the United States, United Kingdom, and Canada (n = 2,727). The net benefit of the top-performing measures to inform treatment initiation were compared using decision curves. Measurements and Main Results: PPF classified according to relative decline in FVC of ≥10%, relative decline in Dl CO of ≥15%, and PPF guideline criteria displayed the best overall test performance, with area under the receiver operating characteristic curves of 0.67–0.68. Specificity was higher than sensitivity for all evaluated measures, with relative measures of lung function decline outperforming absolute measures. The net benefit of standalone relative decline in FVC ≥10% and Dl CO ≥15% was similar to PPF guideline criteria across the range of treatment probability thresholds. Conclusions: Classifying PPF by standalone measures of FVC and Dl CO decline provides clinical utility similar to PPF guideline criteria. Top-performing physiology-based measures of PPF discriminate outcomes with high specificity but low sensitivity.


  • Genetics of interstitial lung diseases: a state-of-the-art review

    by Nicole Ng, Maria Molina-Molina, Ayodeji Adegunsoye, Raphael Borie, Chad A. Newton, Benjamin Raby, David Zhang, Maria Padilla, Bruno Crestani, Marshall S. Horwitz, et al.

    Advancements in genetics and genomics continue to further our understanding of their contributions to the development of interstitial lung diseases (ILDs). This state-of-the-art clinical review synthesises current knowledge of the contribution of genetics when evaluating patients suspected to have ILD. We consider highly penetrant Mendelian disorders as well as common variants conferring smaller risk that act in concert with other genetic and acquired risk factors. Additionally, gene-by-environment and pharmacogenomic interactions are discussed to highlight their impact on disease course. Lastly, the approach to genetic ILDs is reviewed from available testing to future directions.


  • Proteomic Biomarkers of Survival in Non–Idiopathic Pulmonary Fibrosis Interstitial Lung Disease

    by Shehabaldin Alqalyoobi, Jennifer A. Smith, Manoj V. Maddali, Janelle Vu Pugashetti, Chad A. Newton, John S. Kim, Angela L. Linderholm, Ching-Hsien Chen, Shwu-Fan Ma, Swaraj Bose, et al.

    Rationale: Although idiopathic pulmonary fibrosis (IPF) has been widely studied, progressive non-IPF interstitial lung disease (ILD) remains poorly understood. Objectives: To identify and validate proteomic biomarkers of non-IPF ILD survival. Methods: High-throughput proteomic data were generated using plasma collected as part of prospective registries at the universities of California and Texas (discovery cohort; n = 676) and in the PRECISIONS multiomic study (validation cohort; n = 616). Proteins associated with 3-year transplant-free survival (TFS) were identified using multivariable Cox proportional hazards regression, and those associated with TFS after adjustment for false discovery were advanced for validation cohort testing. Pathway analysis was performed to identify molecular pathways unique to non-IPF ILD and shared with IPF. Measurements and Main Results: Of 2,925 proteins tested in the discovery cohort, 73 were associated with TFS, with 44 showing sustained TFS association in the validation cohort. The top TFS-associated proteins were amphiregulin (hazard ratio [HR], 2.51; 95% confidence interval [CI], 2.07–3.04), integrin subunit-β6 (HR, 2.46; 95% CI, 1.95–3.10), and keratin 19 (HR, 1.70; 95% CI, 1.47–1.98). All but one validated biomarker showed consistent TFS association across non-IPF ILD subtypes. Pathway analysis identified several molecular pathways shared with IPF, together with three pathways unique to non-IPF ILD. Conclusions: We identified and validated novel prognostic protein biomarkers in non-IPF ILD, most of which showed consistent association across non-IPF ILD subtypes. Although most biomarkers and molecular pathways identified were previously linked to IPF, several were unique to non-IPF ILD, suggesting that unique biology may contribute to progressive non-IPF ILD.